On Tuesday, Curebase announced a three-year clinical trial partnership with Meru Health, the study looking at the effectiveness of the latter’s 12-week treatment program, developed to reduc
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.
